Biopharma singleplex development — the custom ELISA, MSD S-PLEX, and Simoa single-molecule assays for pharmacokinetics, immunogenicity, and biomarker qualification in drug development representing the highest-value, most technically demanding application — creates the most commercially dynamic market segment, with the Singleplex Immunoassay Market reflecting biopharma as the development-driven commercial driver.

PK/PD assay development — the ligand-binding assays (LBA) for therapeutic monoclonal antibody, bispecific, and ADC pharmacokinetics creating the critical path bioanalytical requirement. FDA requiring validated singleplex assays for all biologics clinical trials, with anti-drug antibody (ADA) and neutralizing antibody (NAb) assays representing 30-40% of bioanalytical CRO revenue and sensitivity requirements reaching 100 ng/mL for high-dose mAbs demonstrates the regulatory commercial impact.

Companion diagnostic co-development — the FDA-approved singleplex companion diagnostics (HercepTest, PD-L1 IHC 22C3, EGFR mutation IHC) requiring simultaneous drug and test development creating the strategic partnership segment. Dako/Agilent, Ventana/Roche, and Leica Biosystems developing singleplex IHC and ISH assays in parallel with oncology drug programs, with the 2023 FDA guidance on co-development mandating early assay alignment.

Biomarker qualification for regulatory submission — the fit-for-purpose singleplex assays for exploratory, probable valid, and known valid biomarkers in the FDA-NIH BEST resource creating the evidentiary hierarchy. Pharmaceutical companies investing $2-5M per biomarker qualification program, with singleplex assays providing the analytical specificity required for regulatory acceptance of patient selection and pharmacodynamic endpoints.

Do you think singleplex companion diagnostics will maintain their regulatory primacy, or will next-generation sequencing and multiplex proteomics achieve biomarker panel qualification that replaces single-analyte patient selection?

What are the specific biopharma singleplex platforms, their sensitivities, and regulatory requirements? PK/PD platforms: ELISA: Meso Scale Discovery (MSD): S-PLEX; electrochemiluminescence; fg/mL; sensitivity; 10-100x; ELISA; Gyrolab: microfluidic; nanoliter; sample; rapid; Simoa (Quanterix): single; molecule; array; attomolar; fg/mL; ultrasensitive; Ella (ProteinSimple): automated; microfluidic; cartridge; RPPA: reverse; phase; protein; array; multiplex; but; single; read; Regulatory: FDA: GLP: non-clinical; bioanalytical; validation; guidance; 2018; GCLP: clinical; trial; bioanalytical; validation; immunogenicity: tiered; approach; screening; confirmatory; titer; NAb; cell-based; ligand-binding; sensitivity: 100-500 ng/mL; standard; 10-50 ng/mL; high; sensitivity; precision: CV <20%; QCs; accuracy: 80-120%; LLOQ; ULOQ; Companion diagnostic: IHC: HercepTest (Dako): HER2; breast; gastric; approved; PD-L1 22C3 (Dako): NSCLC; head; neck; urothelial; gastric; approved; PD-L1 28-8 (Dako): melanoma; NSCLC; approved; PD-L1 SP142 (Ventana): urothelial; TNBC; approved; PD-L1 SP263 (Ventana): NSCLC; urothelial; approved; EGFR pharmDx (Dako): colorectal; NSCLC; approved; ALK (Ventana): NSCLC; approved; ISH: HER2 FISH (PathVysion): breast; approved; ZytoVision: various; FISH; approved; CISH: SPOT-LIGHT; HER2; approved; Requirements: PMA: most; companion; diagnostics; high; risk; 510(k): some; lower; risk; de novo: novel; CLIA: LDT; development; companion; diagnostic; pathway; analytical validation: sensitivity; specificity; PPA; NPA; reproducibility; reader; precision; clinical validation: clinical; trials; retrospective; prospective; co-development; drug; test; simultaneous; Pricing: development: $2-5M; assay; validation; clinical; qualification; commercial: $300-800; per; test; premium; companion; diagnostic; value; based.

How do CROs, reference labs, and pharma internal groups approach singleplex bioanalytical and diagnostic development? CROs: IQVIA: central; lab; bioanalytical; companion; diagnostic; Charles River: bioanalytical; GLP; GCLP; validation; Covance (Labcorp): central; lab; bioanalytical; development; Frontage: bioanalytical; DMPK; Chinese; market; BioAgilytix: bioanalytical; immunogenicity; cell-based; specialty; Reference labs: LabCorp: companion; diagnostic; IHC; FISH; CISH; Quest: companion; diagnostic; development; commercial; ARUP: esoteric; reference; validation; Mayo: clinical; reference; research; Pharma internal: Genentech/Roche: internal; bioanalytical; companion; diagnostic; Dako; partnership; Novartis: internal; external; mixed; strategy; AstraZeneca: external; preferred; CRO; partnership; BMS: internal; companion; diagnostic; development; Merck: internal; external; balanced; Approach: outsourced: 70-80% of bioanalytical; CRO; cost; capacity; expertise; internal: 20-30%; strategic; core; capacity; control; IP; hybrid: internal; development; CRO; validation; clinical; commercial; partnership; Challenges: capacity: peak; demand; pipeline; variable; CRO; bottleneck; quality: GLP; inspection; findings; consistency; timeline: drug; development; pressure; bioanalytical; critical; path; Future: automation: robotics; sample; prep; analysis; reporting; integrated: discovery; development; commercial; seamless; platform; AI: method; development; optimization; prediction; precision: cell; gene; therapy; new; modalities; complex; matrices.